FI3679016T3 - 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja - Google Patents
2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotojaInfo
- Publication number
- FI3679016T3 FI3679016T3 FIEP18854688.1T FI18854688T FI3679016T3 FI 3679016 T3 FI3679016 T3 FI 3679016T3 FI 18854688 T FI18854688 T FI 18854688T FI 3679016 T3 FI3679016 T3 FI 3679016T3
- Authority
- FI
- Finland
- Prior art keywords
- polymorph
- compound
- chloroform
- term
- stated value
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555390P | 2017-09-07 | 2017-09-07 | |
| PCT/US2018/049829 WO2019051147A1 (en) | 2017-09-07 | 2018-09-07 | SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3679016T3 true FI3679016T3 (fi) | 2025-12-12 |
Family
ID=65517772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18854688.1T FI3679016T3 (fi) | 2017-09-07 | 2018-09-07 | 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10669236B2 (enExample) |
| EP (1) | EP3679016B1 (enExample) |
| JP (3) | JP2020533412A (enExample) |
| KR (2) | KR102691700B1 (enExample) |
| CN (2) | CN111278808B (enExample) |
| AU (2) | AU2018330163B2 (enExample) |
| BR (1) | BR112020004419A2 (enExample) |
| CA (1) | CA3074831A1 (enExample) |
| DK (1) | DK3679016T3 (enExample) |
| FI (1) | FI3679016T3 (enExample) |
| IL (1) | IL272992A (enExample) |
| MX (2) | MX2020002622A (enExample) |
| SG (1) | SG11202001868RA (enExample) |
| TW (1) | TWI815820B (enExample) |
| WO (1) | WO2019051147A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| EP4186890A1 (en) | 2021-11-29 | 2023-05-31 | Moehs Ibérica, S.L. | Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin |
| CN115010655A (zh) * | 2022-07-21 | 2022-09-06 | 重庆迈德凯医药有限公司 | 一种替尼布林的纯化方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
| HUP0400446A2 (hu) * | 2001-05-22 | 2004-09-28 | Pfizer Products Inc. | Azitromicin kristályformái |
| US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
| US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| BRPI0519424B8 (pt) | 2004-12-28 | 2021-05-25 | Athenex Inc | compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| JP2008522983A (ja) * | 2005-09-13 | 2008-07-03 | シコール インコーポレイティド | ロクロニウムブロミドの合成方法 |
| DK2041071T3 (da) * | 2006-06-29 | 2014-09-01 | Kinex Pharmaceuticals Llc | Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade |
| BRPI0717554A2 (pt) * | 2006-09-28 | 2013-10-29 | Merck & Co Inc | Composição farmacêutica, método para tratar câncer e aliviar os efeitos colaterais do inibidor da hdac, e, método de se obter um complexo de quelato inibidor da hdac de metal |
| US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| US7935697B2 (en) * | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
| TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
| CN101778855A (zh) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | 替诺福韦酯半富马酸共晶体 |
| WO2015069217A1 (en) | 2013-11-05 | 2015-05-14 | Baylor College Of Medicine | Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis |
| CN106810490A (zh) * | 2017-02-06 | 2017-06-09 | 重庆泰润制药有限公司 | 一种二芳基化合物的晶型及其制备方法和应用 |
| BR112019018687A2 (pt) | 2017-03-10 | 2020-04-07 | Athenex, Inc. | métodos de tratamento e/ou prevenção da ceratose actínica |
-
2018
- 2018-09-07 US US16/124,281 patent/US10669236B2/en active Active
- 2018-09-07 BR BR112020004419-9A patent/BR112020004419A2/pt unknown
- 2018-09-07 FI FIEP18854688.1T patent/FI3679016T3/fi active
- 2018-09-07 SG SG11202001868RA patent/SG11202001868RA/en unknown
- 2018-09-07 WO PCT/US2018/049829 patent/WO2019051147A1/en not_active Ceased
- 2018-09-07 CN CN201880069894.6A patent/CN111278808B/zh active Active
- 2018-09-07 CN CN202410415705.3A patent/CN118439992A/zh active Pending
- 2018-09-07 AU AU2018330163A patent/AU2018330163B2/en active Active
- 2018-09-07 DK DK18854688.1T patent/DK3679016T3/da active
- 2018-09-07 KR KR1020207010105A patent/KR102691700B1/ko active Active
- 2018-09-07 EP EP18854688.1A patent/EP3679016B1/en active Active
- 2018-09-07 MX MX2020002622A patent/MX2020002622A/es unknown
- 2018-09-07 TW TW107131540A patent/TWI815820B/zh active
- 2018-09-07 CA CA3074831A patent/CA3074831A1/en active Pending
- 2018-09-07 JP JP2020536496A patent/JP2020533412A/ja active Pending
- 2018-09-07 KR KR1020247025684A patent/KR20240119192A/ko active Pending
-
2020
- 2020-03-01 IL IL272992A patent/IL272992A/en unknown
- 2020-03-06 MX MX2023001805A patent/MX2023001805A/es unknown
- 2020-04-27 US US16/858,854 patent/US11230527B2/en active Active
-
2021
- 2021-12-09 US US17/546,133 patent/US12215083B2/en active Active
-
2023
- 2023-02-21 AU AU2023201010A patent/AU2023201010B2/en active Active
- 2023-06-30 JP JP2023107781A patent/JP2023157909A/ja active Pending
-
2024
- 2024-12-19 US US18/987,655 patent/US20250115555A1/en active Pending
-
2025
- 2025-06-02 JP JP2025091579A patent/JP2025131661A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6964096B2 (ja) | ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| DK2900269T3 (en) | COMBINATION OF REGORAFENIB AND ACETYLSALICYLIC ACID FOR TREATMENT OF COLORECTAL CANCER. | |
| EP2959900B1 (en) | Compound for treatment of cancer | |
| JP2015512942A5 (enExample) | ||
| CA2519301A1 (en) | Oxime derivatives and their use as pharmaceutically active agents | |
| FI3679016T3 (fi) | 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja | |
| JP2013542267A5 (enExample) | ||
| WO2018031707A1 (en) | Acyl benzo[d]thiazol-2-amine and their methods of use | |
| JP2016525104A5 (enExample) | ||
| MX2023014436A (es) | Compuestos de 3-pirrolilsulfonamida como antagonistas de gpr17. | |
| AU2015204609B2 (en) | Novel functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy | |
| EP3524250B1 (en) | Pharmaceutical composition comprising a neutral endopeptidase (nep) inhibitor and an azilsartan ester derivative and use thereof for treating cardiovascular diseases | |
| CA2813063A1 (en) | Antagonist for mutated androgen receptor | |
| WO2014138505A1 (en) | Treatment of cancer and other conditions using a transcription factor modulator | |
| US11124489B2 (en) | EPAC antagonists | |
| WO2015039073A1 (en) | Polysubstituted pyrroles having microtubule-disrupting, cytotoxic and antitumor activities and methds of use thereof | |
| WO2019170135A1 (zh) | 药物组合物的制备方法 | |
| JP5955531B2 (ja) | 抗癌剤 | |
| CN110237071B (zh) | 药物制剂及其应用 | |
| WO2013066834A1 (en) | Compounds and methods | |
| KR101939855B1 (ko) | 디아릴피리다지논 유도체, 이의 제조방법 및 인간치료에서의 용도 | |
| RU2023122465A (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
| KR20180013755A (ko) | 항암용 약학 조성물 | |
| JP2023134657A (ja) | 新規抗腫瘍剤 | |
| US20160194281A1 (en) | Crystalline forms of silodosin |